DexCom DXCM3.23%increase; green up pointing triangle received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is ...

Investors with a lot of money to spend have taken a bullish stance on DexCom DXCM. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Dexcom stock plunged to a four-month low Monday after the FDA issued a warning letter tied to inspections of two facilities in the U.S. DexCom (NasdaqGS:DXCM) recently received a warning letter ...

DexCom (DXCM) closed the most recent trading day at $134.17, moving -0.41% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.57%. On the other hand ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company. It focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems.

Management believes organic revenue is a meaningful metric to investors as it provides a more consistent comparison of Dexcom’s revenue to prior periods as well as to industry peers. We exclude ...

Analyst Price Forecast Suggests 14.60% Upside As of January 28, 2025, the average one-year price target for DexCom is $99.51/share. The forecasts range from a low of $75.75 to a high of $131.25.

Bengaluru: Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following inspections of its two key manufacturing facilities, sending its ...

On Thursday, Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion. U.S. revenue rose by 4% ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 29.6 ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products ...